Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 8/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427886 | 0.87 | EHMT2 (0.48) | KDM1ARCOR1EHMT2APP | |
| SCHEMBL1427704 | 0.87 | EHMT2 (0.48) | KDM1ARCOR1EHMT2APP | |
| Ammonia Solution, Strong SCHEMBL4201050 | 0.85 | EHMT2 (0.44) | KDM1ARCOR1EHMT2 | |
| Ammonia Solution, Strong SCHEMBL4198136 | 0.83 | KDM1A (0.39) | KDM1ARCOR1EHMT2MEN1KMT2A | |
| SCHEMBL1427960 | 0.82 | EHMT2 (0.50) | KDM1ARCOR1EHMT2APP | |
| SCHEMBL1427813 | 0.76 | EHMT2 (0.51) | KDM1ARCOR1EHMT2APP | |
| SCHEMBL1428467 | 0.75 | EHMT2 (0.49) | KDM1ARCOR1EHMT2APP | |
| SCHEMBL1428447 | 0.75 | EHMT2 (0.55) | KDM1ARCOR1EHMT2 | |
| SCHEMBL4207153 | 0.73 | EHMT2 (0.48) | KDM1ARCOR1EHMT2APP | |
| SCHEMBL4202905 | 0.73 | EHMT2 (0.49) | KDM1ARCOR1EHMT2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | CXCR4, CXCR2, CXCL12 | KDM1A 4804/4885RCOR1 3069/4885EHMT2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.